Monzani Maria Laura, Pederzoli Simone, Volpi Laura, Magnani Elisa, Diazzi Chiara, Rochira Vincenzo
Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy.
J Endocr Soc. 2021 Jan 13;5(3):bvab002. doi: 10.1210/jendso/bvab002. eCollection 2021 Mar 1.
Although sexuality influences well-being and quality of life (QoL), studies on sexual dysfunction (SD) in adult growth hormone deficiency (AGHD) patients are lacking.
To investigate the prevalence of SD in AGHD patients grouped according to recombinant human growth hormone (r-hGH) therapy.
Prospective, cross-over, 24 months, monocentric study.
Real-life clinical setting in a tertiary, endocrinological center.
83 AGHD patients (31 women, 52 men, mean age 56.3 ± 14.7 years) were enrolled according to stringent criteria.
Patients already on long-term r-hGH therapy (Group 1, n = 32) untreated (Group 2, n = 51).
Serum hormones, QoL Satisfaction in Hypopituitarism (QLS-H) and QoL Assessment of GHD in Adults (QoL-AGHDA) questionnaires for QoL, Index for Erectile Function-15 (IIEF-15) in men, and Female Sexual Function Index (FSFI) in women for SD.
The overall prevalence of SD was 71.2% (60% men, 89% women). All IIEF-15 scores were lower ( = 0.001) and erectile dysfunction was more prevalent in Group 2 (75%) than Group 1 (35%). IGF-1 was correlated to scores of all IIEF-15 domains, particularly with that of erectile function (EF) (R=0.123, = 0.019). EF domain score correlated with QLS-H ( < 0.005) and QoL-AGHDA ( = 0.001). Despite the high prevalence of female SD also in untreated AGHD women, FSFI scores did not correlate with IGF-1 levels and QoL scores.
SD is highly prevalent in AGHD patients, especially in those untreated. SD represents an overlooked and neglected issue in AGHD, regardless the contribution of sexual life on QoL. The evaluation of sexual function should be integrated in the global assessment of AGHD patients.
尽管性功能会影响幸福感和生活质量（QoL），但关于成年人生长激素缺乏症（AGHD）患者性功能障碍（SD）的研究仍很匮乏。
调查根据重组人生长激素（r-hGH）治疗分组的AGHD患者中SD的患病率。
前瞻性、交叉、为期24个月的单中心研究。
一家三级内分泌中心的实际临床环境。
根据严格标准招募了83例AGHD患者（31名女性，52名男性，平均年龄56.3±14.7岁）。
已经接受长期r-hGH治疗的患者（第1组，n = 32）与未治疗患者（第2组，n = 51）。
血清激素、用于评估生活质量的垂体功能减退症生活质量满意度（QLS-H）问卷和成人GHD生活质量评估（QoL-AGHDA）问卷、男性勃起功能指数-15（IIEF-15）以及女性性功能障碍的女性性功能指数（FSFI）。
SD的总体患病率为71.2%（男性为60%，女性为89%）。所有IIEF-15评分均较低（P = 0.001），且第2组（75%）的勃起功能障碍比第1组（35%）更为普遍。IGF-1与所有IIEF-15领域的评分相关，尤其是与勃起功能（EF）评分相关（R = 0.123，P = 0.019）。EF领域评分与QLS-H（P < 0.005）和QoL-AGHDA（P = 0.001）相关。尽管未治疗的AGHD女性中女性SD的患病率也很高，但FSFI评分与IGF-1水平和生活质量评分无关。
SD在AGHD患者中非常普遍，尤其是在未治疗的患者中。无论性生活对生活质量的影响如何，SD在AGHD中都是一个被忽视的问题。性功能评估应纳入AGHD患者的整体评估中。
